Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Accountability for Low-value Deals
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Comment by greaterfoolFredon May 12, 2022 3:38pm
154 Views
Post# 34679101

RE:RE:Accountability for Low-value Deals

RE:RE:Accountability for Low-value Deals
Georgeparros wrote: Hi jd,

Would you say DrDR or John Proffett are out of line? I thought Shadow Lake Group were the expert in valuing a collaboration between xB3 and a licensee.

I think the more the merrier. It's one drug, no exclusivity, and we don't know the royalty rate. We got cash from a private biotech company, probably operating at a loss? Steal imho.

I think getting one million from this Korean company is harder than getting 25 from a BP.

GP

I think it's a good deal.  At this point any deal is a good deal.  I say let any pharma that wants to, try one drug for no payment, just milestones and royalty.  All we need is one success to change the game.  Then no more freebies.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities